Seeking Alpha

NuVasive (NUVA +13%) moves up after beating on its Q3 bottom and top line numbers today. The...

NuVasive (NUVA +13%) moves up after beating on its Q3 bottom and top line numbers today. The company lowers guidance going forward, now expecting FY12 revenue of between $601M to $606M on earnings of $0.88 to $0.90 per share. However, the company also noted that it's aggressively moving to replenish its diminished salesforce that led to flat third-quarter sales growth in its spinal division.
Comments (1)
  • anil92691
    , contributor
    Comments (397) | Send Message
     
    Nuvasive should spend some money on lobbyists to stop orthopedic surgeons from starting marketing companies and using the products marketed on their patients. This conflict of interest is awful for patients and pricing. The Sunshine Act's objective is to stop this conflict of interest. However it has to be seen if this helps.
    24 Oct 2012, 05:16 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector